November 8, 2023
GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers
Sabrina Genssler, Daniel Schaetzlein, Eugen Leo, Markus Haake and Christine Schuberth-Wagner /...
Read More
November 8, 2023
SHP-1 is a central mediator of GDF-15 mediated adhesion inhibition in T-cells
Markus Haake, Neha Vashist, Beatrice Haack, Birgitt Fischer, Kristin Eichler, Matthias Kist,...
Read More
October 31, 2023
CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition...
Read More
October 11, 2021
CatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...
CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...
Read More
September 30, 2021
CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...
CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...
Read More
August 25, 2021
GDF-15 contributes to proliferation and immune escape of malignant gliomas
P. Roth, M. Junker, I. Tritschler, M. Mittelbronn, Y. Dombrowski, S. N....
Read More